Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06270043 · ClinicalTrials.gov registry record

Focal Therapy for Localized Prostate Cancer

A clinical trial of Prostate Cancer, sponsored by University of California, San Diego.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06270043 is a study of Prostate Cancer that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 500 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06270043, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.

Conditions Studied

Interventions

  • PROCEDURE Focal Therapy

Study Locations (1)

California

  • University of California, San Diego - La Jolla

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-02-01
Est. Completion 2034-02-01

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06270043

The ClinicalTrials.gov registry entry for NCT06270043 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Focal Therapy is the first listed.

NCT06270043 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06270043 about?

NCT06270043 is a clinical study titled "Focal Therapy for Localized Prostate Cancer". This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.

What is the current status of trial NCT06270043?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-02-01. Estimated completion is 2034-02-01.

What conditions does trial NCT06270043 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06270043?

The interventions under investigation include: Focal Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT06270043?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06270043 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.